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DESIGN: We conducted a prospective, candidate gene study to test for as-
sociations between genetic variants and both subjective weight gain and
objective weight changes in ENG implant users.
MATERIALS ANDMETHODS: We recruited healthy, reproductive-aged
women using ENG implants for 12-36 months. We asked participants about
subjective weight gain (yes/no) during contraceptive implant use and per-
formed medical record review to calculate objective weight changes from
implant insertion to study enrollment. We genotyped each participant for
120 single nucleotide polymorphisms (SNPs) in 14 genes involved in proges-
tin metabolism, regulation, and function. To identify genetic variants associ-
ated with subjectiveweight gain and objectiveweight changes, we performed
backwards stepwise multivariable logistic regression and generalized linear
modeling, respectively, adjusting for age, body-mass index (BMI), and
self-reported race/ethnicity.
RESULTS: We enrolled 350 ethnically-diverse participants. Median BMI
was 26.0 kg/m2 (range 18.5-52.0) and 41.4% reported experiencing subjec-
tive weight gain during contraceptive implant use. Weight at time of implant
insertion was available for 276 participants with a mean weight change of
+3.8 kg (7.2). We found two genetic variants significantly associated
with subjective weight gain. Carriers of CYP3A4*1G and participants homo-
zygous for the ESR1 rs9322335 variant were both more likely to report
weight gain (aOR 2.32, p¼0.001 and aOR 2.41, p¼0.001, respectively). Fre-
quencies of these genetic variants were 33.3% and 68.1%, respectively. We
found two genetic variants associated with objective weight changes. Partic-
ipants homozygous for the ESR1 rs9340799 variant gained 10 kg more
weight, on average, compared to all other participants (b¼ 10.09,
p¼0.002). Carriers of the CYP2C19 rs7088784 variant lost 3.9 kg more
weight, on average, compared to all other participants (b¼ -3.88,
p¼0.001). Frequencies of these genetic variants were 8.3% and 22.5%,
respectively. Higher BMI was the only variable significantly associated
with both outcomes: aOR 1.10 (p¼1.6x10-5) and b¼ 0.56 (p¼6.3x10-13).
CONCLUSIONS: We identified two genetic variants in the ESR1 (estro-
gen receptor 1) gene that were associated with subjective and objective
weight gain in ENG contraceptive implant users. Neither SNP (rs9322335
or rs9340799) has known associations with obesity or metabolic syndrome,
and thus, this may be a progestin-dependent effect. Additional genetic
research is needed to facilitate advances in individualized counseling on
the risk of weight gain with exogenous steroid hormones.
SUPPORT: This work was primarily supported by the Society of Family
Planning Research Fund [grant number SFPRF17-3]. This work was also
supported by NIH/NCATS Colorado CTSA Grant Number UL1
TR001082. Dr. Lazorwitz’s time is also supported by the NICHD K12
Women’s Reproductive Health Research Scholar Program (grant number
5K12HD001271-18). Contents are the authors’ sole responsibility and do
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VAGINAL PH-REGULATOR: RESULTS FROM THE
PHASE 3, AMPOWER CONTRACEPTION CLINICAL
TRIAL. Michael A. Thomas, MD,a Kelly R. Culwell, MD,
MPH,b Clint Dart, MS,c Brandi Howard, PhDb aUniversity of Cincinnati,
Cincinnati, OH; bEvofem, Inc., San Diego, CA; cHealth Decisions, Durham,
NC.
OBJECTIVE: Amphora (formerly known as Acidform), a multipurpose
vaginal pH-regulator (MVP-R), is a novel, non-hormonal, woman-
controlled, on-demand, water-based, petroleum-free vaginal gel being inves-
tigated for prevention of pregnancy and sexually transmitted infections. Here
we present primary results from the confirmatory phase 3 contraception trial,
AMPOWER.
DESIGN: This was a single-arm, open-label study conducted at 112 sites
within the US (ClinicalTrials.gov number NCT03243305).
MATERIALS AND METHODS: All sites obtained IRB approval and all
women provided informed consent. Eligibility criteria included healthy,
monogamous, sexually active women aged 18-35 years who had normal cy-
clic menses of length 21-35 days, reported having intercourseR3 times per
cycle, and were willing to use the study drug as the only method of contra-
ception over the course of the study. Women were instructed to administer
a single prefilled applicator of study drug intravaginally immediately before
or up to 1 hour before each episode of vaginal intercourse. Women used eD-
iaries to record timing of product administration, coital information, and side
effects. The primary efficacy analysis was the cumulative pregnancy percent-
age over 7 cycles with typical-use calculated by the Kaplan-Meier method.e10 ASRM Abstracts
Downloaded for Anonymous User (n/a) at University of Arizon
For personal use only. No other uses without permission.RESULTS: A total of 1384 women were included in the Intent-to-Treat
(ITT) population, 1182 were included in the primary efficacy analysis
(modified ITT [mITT]), and 1330 used at least 1 application of study prod-
uct and were included in the Safety population. In the ITT population,
select baseline characteristics were as follows: mean age, 27.7 years (stan-
dard deviation [SD], 4.5); mean body mass index, 28.7 kg/m2 (SD, 8.1);
Caucasian, 69.0% (955/1384); and non-Hispanic or non-Latino origin,
58.2% (805/1384). The mean number of prior pregnancies was 2.5 (SD,
1.8) and the most common contraceptive methods used immediately prior
to enrollment were reported to be male condom (56.9% [787/1384], with-
drawal method (14.2% [196/1384]), and rhythm method (5.1%, 70/1384).
Fewer than 2% of study participants discontinued due to adverse events
(AEs) (1.7% [23/1384]). For the primary efficacy analysis in the mITT pop-
ulation, the 7-cycle cumulative pregnancy percentage with typical-use was
13.9% (95% confidence interval [CI]; 10.0%, 17.8%), which met the pre-
specified primary endpoint of having the upper bound 95% CI %21%.
The most common AEs (>2.0%) were vulvovaginal burning sensation
(20.0%, 266/1330), vulvovaginal pruritus (11.2%, 149/1330), urinary tract
infection (5.7%, 76/1330), vulvovaginal pain (3.8%, 51/1330), vulvovagi-
nal mycotic infection (2.9%, 38/1330), bacterial vaginosis (2.8% [37/
1330]), and nasopharyngitis (2.6% [35/1330]). Fourteen women (1.1%)
experienced a serious AE with only 1 event (cystitis, 0.1%) considered
treatment related.
CONCLUSIONS: In this large phase 3 study, the MVP-R, Amphora, was
found to be safe and effective in preventing pregnancy. Amphora provides
women with an important new non-hormonal, woman-controlled contracep-
tive option.
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OBJECTIVE: We analyzed bleeding patterns and endometrial safety of a
contraceptive vaginal system (CVS) releasing a daily mean of segesterone
acetate (SA) 0.15 mg and ethinyl estradiol (EE) 0.013 mg for up to 13 cycles
of use.
DESIGN: Two multicenter, single-arm, open-label, pivotal, phase 3
studies of the SA/EE CVS conducted at 20 US and 7 international sites (3
in Europe, 3 in Latin America, 1 in Australia).
MATERIALS ANDMETHODS: Participants initiated CVS use on day 2-
5 of their menstrual cycle, followed a 21/7-day in/out schedule of CVS use
for up to 13 cycles, and recorded vaginal bleeding in paper diaries. We sum-
marized scheduled (occurring on cycle days 22-28) and unscheduled
bleeding/spotting (occurring on cycle days 1 to 21) by 28-day cycles.We per-
formed multiple logistic regression analyses to identify factors associated
with unscheduled bleeding/spotting from the first 4 cycles of CVS use.
Women could also participate in an endometrial safety sub-study at 5 sites.
Three blinded pathologists examined histology of endometrial biopsies ob-
tained at screening, at cycle 6 (first 25 women reaching 6 cycles), and at
end of study (cycle 12/13) or early study termination in the remaining
women.We excluded womenwith endometrial hyperplasia or cancer at base-
line and evaluated histologic changes in women with both screening and
follow-up biopsies.
RESULTS: We analyzed bleeding data from the 2070 of 2308 participants
in the two phase 3 studies who had daily bleeding diary data for cycle control
analysis. Most women (97.9%) documented scheduled bleeding/spotting
(during ring removal days) with a mean of 4.6–5.2 scheduled bleeding/spot-
ting days per cycle. The proportion of women reporting any unscheduled
bleeding/spotting occurred in 13.2%-21.7% of women per cycle with a
mean of 3.4–5.1 days per cycle for those who had unscheduled bleeding.
Absence of scheduled bleeding/spotting was 5%-8% of women per cycle;
absence of any bleeding/spotting (complete amenorrhea) was 2.6%-4.9%
of women per cycle. A low percentage of women (1.7%) discontinued early
due to unacceptable bleeding.Vol. 112, No. 3, Supplement, September 2019
a from ClinicalKey.com by Elsevier on October 29, 2019.
 Copyright ©2019. Elsevier Inc. All rights reserved.
Of the 156 women in the endometrial safety sub-study, 83 had follow-up
biopsies. Pathologists reported no cases of endometrial hyperplasia or carci-
noma at cycle 6 (n¼24), cycles 12/13 (n¼30) or other end of therapy times
(n¼29). The most frequent histologic diagnoses were atrophic/inactive or
secretory; atrophic/inactive (cycle 6: 29%, cycles 12/13: 27%, and other
end times: 28%, respectively), secretory (29%, 37%, and 45%, respectively),
proliferative (17%, 7%, and 21%, respectively), mixed (17%, 10% and 3%,
respectively), menstrual (4%, 7%, and 0%, respectively), or insufficient/no
tissue (0%, 10%, and 3%, respectively).
CONCLUSIONS: Women using the SA/EE CVS (FDA approved in
August 2018) for up to 13 cycles experienced good cycle control with few
bleeding discontinuations, and did not have any unexpected endometrial his-
tology safety findings.
SUPPORT: The Eunice Kennedy Shriver National Institute of Child Health
and Human Development of the National Institutes of Health (NICHD; Con-
tract Number HHSN27500403372) funded and conducted the US study; the
US Agency for International Development (USAID; Grant Number GPO-
A-00-04-00019-00) funded the international study, which was conducted by
the Population Council; theWorld Health Organization (WHO) Reproductive
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ICM-A 181 72%(65 – 79%) 57%(50 – 65%)
ICM-B 1088 70%(67 – 72%) 55%(52 – 59%)
ICM-C 54 37%(24 – 51%) 31%(18 – 44%)
TE-a 37 71%(57 – 85%) 67%(51 – 84%)
TE-b 1149 69%(67 – 72%) 56%(52 – 59%)




ICM-A + TE-a 23 75%(61 – 89%) 71%(55 – 87%)
ICM-B + TE-a 14 73%(58 – 87%) 68%(52 – 86%)
ICM-A + TE-b 158 73%(66 – 80%) 59%(51 – 67%)
ICM-B + TE-b 950 71%(68 – 74%) 57%(53 – 60%)
ICM-C + TE-b 41 38%(24 – 52%) 32%(18 – 45%)
ICM-B + TE-c 124 60%(51 – 69%) 44%(35 – 53%)
ICM-C + TE-c 13 32%(20 – 44%) 25%(13 – 36%)
No combinations of ICM-A + TE-c or ICM-C + TE-a were present in the
sample so these probabilities are not shown.Maria Giulia Minasi, M Sc, Alessandra Arnone, M Sc, Valentina Casciani,
PhD, Graciela Estela Cognigni, MD, Rita Vi~noles, MD,
Maria Teresa Varricchio, MD, Luis Alberto Quintero, MD,
Ermanno Greco, MD, Marco Filicori, MD, GynePro Medical Centers- Nexct-
Clinics International, Bologna, Italy.
OBJECTIVE:We have previously demonstrated that it is possible to warm
vitrified human oocytes using a ‘‘universal warming protocol’’ based on sub-
sequent steps with 1M and 0.5 M of ECCP regardless of the warming kit
brand; this study investigated the clinical efficiency of this protocol on ship-
ped oocytes in a transnational donor program.
DESIGN: Retrospective multi-center observational study on a cohort of
238 patients enrolled in egg donation programs from 02 March 2017 to 19
September 2018. Primary endpoint was the survival rate (n oocytes surviv-
ing/ n oocytes warmed). Secondary endpoints were fertilization rate (n
fertilized oocytes / n injected oocytes), blastulation rate (nblastocysts ob-
tained / n fertilized oocytes), implantation rate (nimplanted embryos / n
of transferred embryos) and live birth rate (n of pregnancies giving births
/n of embryo transfer).
MATERIALS AND METHODS: Donated oocytes vitrified in Spain,
warmed in 2 centers in Italy where ICSI and embryo transfer (ET) were per-
formed. Number of oocytes 1898, ET 238. Vitrification with Vitrification Kit
(Kitazato, Japan); warming with two different kits: Kitazato Warming Kit
and Vit Kit-Thaw (Irvine-Fujifilm, US). Warmed oocytes assigned to 2
groups: KK (Kitazato/Kitazato) 939, and KI (Kitazato/Irvine-Fujifilm)
959. Vitrification with Cryotop (Kitazato); embryo culture with Embryo-
scope (Vitrolife, Sweden). ET at blastocyst stage.
RESULTS: Mean age of donors and recipients was comparable. Survival,
fertilization, blastulation and implantation rates were all statistically compa-
rable between the study groups. Survival rate was 84.6% (795/939) in group
KK vs 82.1% (787/959) in group KI. Fertilization rate was 75.7% (602/795)
vs 80.4% (633/787), and blastulation rate 58.5% (352/602) vs 57.8% (366/
633). Implantation rate was 38.3 % (80/209) in group KK vs 45.9% (84/
183) in group KI. Live birth rate was 52.5% (62/118) in KK and 45.0%
(54/120) in KI.
CONCLUSIONS: The proven clinical efficiency of this ‘‘universal warm-
ing protocol’’ with ready-to-usewarming kits with 1 and 0.5M of ECCP sim-
plifies vitrified oocyte exchange between AR centers in different countries,
overcoming potential regulatory/commercial/availability differences
affecting clinical practice.
References: Parmegiani L, Tatone C, Cognigni GE, Bernardi S, Troilo E,
Arnone A, Maccarini AM, Di Emidio G, Vitti M, Filicori M. warming in-
creases survival of slow-frozen sibling oocytes: a step towards a singlewarm-
ing procedure irrespective of the freezing protocol?Reprod Biomed Online.
2014 May;28(5).FERTILITY & STERILITY
Downloaded for Anonymous User (n/a) at University of Arizon
For personal use only. No other uses without permission.Parmegiani L, Beilby KH, Arnone A, Bernardi S, Maccarini AM, Nardi
E, Cognigni GE, Filicori M.Testing the efficacy and efficiency of a single
‘‘universal warming protocol’’ for vitrified human embryos: prospective ran-
domized controlled trial and retrospective longitudinal cohort study.A^ J
Assist Reprod Genet. 2018 Oct;35(10):1887-1895.
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TROPHECTODERM (TE)AREPREDICTIVEOFPREG-
NANCY OUTCOMES. Sarah Druckenmiller, MD,aNicole Noyes, MD,b Megan E. Sutter, PhD,a David H. McCulloh, Ph.D.,c
James A. Grifo, MD, PhDc aNYU Langone Health, New York, NY;
bNorthwell Health, New York, NY; cNYU Langone Prelude Fertility Center,
New York, NY.
OBJECTIVE:Morphologic grading of embryos has been an ART standard
for nearly 4 decades. More recently, PGT-A has improved embryo selection.
Data conflicts regarding whether morphological evaluation improves out-
comes of euploid embryo transfers [1, 2, 3]. Our objective was to determine
whether morphology is predictive of pregnancy outcomes among single
thawed euploid embryo transfers (STEETs).
DESIGN: Retrospective cohort study.
MATERIALSANDMETHODS:We reviewed all STEETs at a university-
based ART center from 2014-2018. STEETs were excluded if oocytes were
cryopreserved, embryos were created at another facility, embryos were
frozen or biopsied twice, PGT-M or -SR was used, or an oocyte donor or
gestational carrier was used. Only the first STEET during the study period
that did not meet any exclusion criterion from each patient was included. Em-
bryo morphology was graded according to Gardner [4]. Outcomes included
implantation rate of all transfers and live birth (LB) rate, excluding 154
ongoing pregnancies and 28 pregnancies with unknown birth outcomes. Sta-
tistical analysis included chi-square, one-way ANOVA, and 2 multivariable
log-binomial regression models to determine the association of predictors
(age, expansion, ICM, TE) with implantation and LB.
RESULTS: We reviewed 1323 STEETs (mean age 37y; range 24-46y).
Overall, implantation was 69% and LB (n¼1141) was 55%. ICM and TE
were bivariately associated with both implantation and LB (p<0.01), but
age and expansion were not. ICM significantly predicted implantation, but
TE did not. Both ICM and TE independently predicted LB (see Table for
adjusted predicted probabilities of implantation and LB based on ICM and
TE grades at mean levels of all covariates in the models).
CONCLUSIONS: Ploidy status is not the sole determinant of embryo
competence. ICM and TE are strong predictors of LB and can improve selec-
tion among euploid embryos. Poor ICM is the greatest negative morpholog-
ical predictor of implantation and LB. Our model can serve as a counseling
tool for patients banking embryos.e11
a from ClinicalKey.com by Elsevier on October 29, 2019.
 Copyright ©2019. Elsevier Inc. All rights reserved.
